All data are based on the daily closing price as of May 23, 2024

SK C&C Gains Approval for AI-Based Stroke Diagnosis Tool

South Korea's SK C&C's new AI solution, Medical Insight+ Brain Infarct, promises rapid and accurate stroke diagnoses, enhancing patient care
South Korea
s 034730.KO Mid and Small Cap 2000
Share this on

At the end of last year, SK Inc C&C – the information technology service arm of the SK Group in South Korea – revealed an exciting development in medical technology, an innovative artificial intelligence (AI) solution, Medical Insight+ Brain Infarct, set to receive approval from the Ministry of Food and Drug Safety. Medical Insight+ Brain Infarct is designed to quickly and accurately diagnose cerebral infarction, detecting abnormalities in medical image data from thousands of patients using SK C&C’s advanced deep learning algorithm.

To ensure the highest levels of accuracy, SK C&C validated the solution and its diagnostic accuracy with neuroradiologists from leading medical institutions including Seoul National University Hospital. The AI solution rapidly processes non-contrast head CT scan images, identifying and categorizing brain abnormalities into seven degrees of severity to quickly arm medical professionals with information to make decisions about patient treatment.

Medical Insight+ Brain Infarct highlights abnormal areas of the brain with heat maps and outlines, helping doctors catch spots they might otherwise overlook. SK C&C plans to bundle the solution with another of its products, Medical Insight+ Brain Hemorrhage, which received approval in 2021 to identify cerebral hemorrhage, effectively combining the diagnosis processes for both types of stroke. This approval is an important step for SK C&C in the realm of medical technology, demonstrating the power of AI to revolutionize not only stroke diagnosis, but ultimately, treatment and outcomes for patients.

Share this on
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top